NBI 31772

Drug Profile

NBI 31772

Latest Information Update: 21 Nov 2007

Price : $50

At a glance

  • Originator Neurocrine Biosciences
  • Class Catechols; Isoquinolines; Small molecules
  • Mechanism of Action Insulin-like growth factor I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetes mellitus

Most Recent Events

  • 21 Nov 2005 Discontinued - Preclinical for Diabetes mellitus in USA (unspecified route)
  • 01 Sep 2003 No development reported - Preclinical for Diabetes mellitus in USA (unspecified route)
  • 12 Mar 2002 Preclinical trials in Diabetes mellitus in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top